A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma

被引：3
|
作者：
Wen, Patrick V.
Omuro, Antonio M.
Batchelor, Tracy T.
Lai, Albert
Mellinghoff, Ingo K.
Nghiemphu, Leia
Norden, Andrew
Gendreau, Steven B.
Laird, A. Douglas
Nguyen, Linh
Cloughesy, Timothy
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-09-B265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B265
引用
收藏
页数：3
相关论文
共 38 条
  • [31] First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
    Wicki, Andreas
    Brown, Nicholas
    Xyrafas, Alexandros
    Bize, Vincent
    Hawle, Hanne
    Berardi, Simona
    Cmiljanovic, Natasa
    Cmiljanovic, Vladimir
    Stumm, Michael
    Dimitrijevic, Sasa
    Herrmann, Richard
    Pretre, Vincent
    Ritschard, Reto
    Tzankov, Alexandar
    Hess, Viviane
    Childs, Alexa
    Hierro, Cinta
    Rodon, Jordi
    Hess, Dagmar
    Joerger, Markus
    von Moos, Roger
    Sessa, Cristiana
    Kristeleit, Rebecca
    EUROPEAN JOURNAL OF CANCER, 2018, 96 : 6 - 16
  • [32] Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
    Subbiah, Vivek
    Coleman, Niamh
    Piha-Paul, Sarina A.
    Tsimberidou, Apostolia M.
    Janku, Filip
    Rodon, Jordi
    Pant, Shubham
    Dumbrava, Ecaterina E. Ileana
    Fu, Siqing
    Hong, David S.
    Zhang, Shizhen
    Sun, Ming
    Jiang, Yunfang
    Roszik, Jason
    Song, Juhee
    Yuan, Ying
    Meric-Bernstam, Funda
    Naing, Aung
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (02): : 378 - 387
  • [33] A Phase lb Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer
    Krop, I. E.
    Wolff, A. C.
    Winer, E. P.
    Miller, K. D.
    Park, B. H.
    Ware, J.
    Holden, S.
    Levy, G. G.
    Derynck, M.
    Storniolo, A. M.
    CANCER RESEARCH, 2010, 70
  • [34] A first in human phase I study of AZD81 86, a potent and selective inhibitor of PI3K in patients with advanced solid tumours as monotherapy and in combination with the dual mTORC1/2 inhibitor vistusertib (AZD2014) or abiraterone acetate.
    Hansen, Aaron Richard
    Shapiro, Geoffrey
    Do, Khanh T.
    Kumar, Rajiv
    Martin-Liberal, Juan
    Higano, Celestia S.
    Wisinski, Kari Braun
    Dean, Emma Jane
    Heath, Elisabeth I.
    Dana, E. Rathkopf
    Linch, Mark David
    Barry, Simon T.
    Brugger, Wolfram
    De Bruin, Elza
    Colebrook, Steve
    Klinowska, Teresa
    Mitchell, Patrick D.
    Moorthy, Ganesh
    De Bono, Johann S.
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study
    Luu, M.
    Vabres, P.
    Devilliers, H.
    Loffroy, R.
    Phan, A.
    Martin, L.
    Morice-Picard, F.
    Petit, F.
    Willems, M.
    Bessis, D.
    Jacquemont, M. L.
    Maruani, A.
    Chiaverini, C.
    Mirault, T.
    Clayton-Smith, J.
    Carpentier, M.
    Fleck, C.
    Maurer, A.
    Yousfi, M.
    Parker, V. E. R.
    Semple, R. K.
    Bardou, M.
    Faivre, L.
    GENETICS IN MEDICINE, 2021, 23 (12) : 2433 - 2442
  • [36] A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.
    Bedard, Philippe
    Tabernero, Josep
    Kurzrock, Razelle
    Britten, Carolyn D.
    Stathis, Anastasios
    Manuel Perez-Garcia, Jose
    Zubel, Angela
    Le, Ngocdiep T.
    Carter, Kirsten
    Bellew, Kevin M.
    Gallarati, Chiara
    Niazi, Faiz
    Demanse, David
    De Buck, Stefan S.
    Sessa, Cristiana
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer
    Britten, C.
    Wainberg, Z.
    Tabernero, J.
    Alsina Maqueda, M.
    Leong, S.
    Sessa, C.
    Millham, R.
    Gallo, J.
    Siu, L.
    Brana, I.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 109 - 109
  • [38] POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.
    Baird, Richard D.
    Van Rossum, Annelot
    Oliveira, Mafalda
    Beelen, Karin
    Garcia-Corbacho, Javier
    Mandjes, Ingrid A. M.
    Vallier, Anne-Laure
    van Werkhoven, Erik D.
    Kumar, Sanjeev Srinivas
    van Tinteren, Harm
    Beddowes, Emma
    Rosing, Hilde
    Schrier, Mariette
    Schultink, Aurelia de Vries
    Saura, Cristina
    Bernards, Rene
    Tabernero, Josep
    Cortes, Javier
    Caldas, Carlos
    Linn, Sabine C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
1234